Earnings summaries and quarterly performance for ALUMIS.
Executive leadership at ALUMIS.
Martin Babler
Detailed
President and Chief Executive Officer
CEO
DG
David Goldstein
Detailed
Chief Scientific Officer
DR
Derrick Richardson
Detailed
Senior Vice President of People and Culture
JS
John Schroer
Detailed
Chief Financial Officer
JD
Jörn Drappa
Detailed
Chief Medical Officer
MB
Mark Bradley
Detailed
Chief Development Officer
RH
Roy Hardiman
Detailed
Chief Business and Strategy Officer
SP
Sanam Pangali
Detailed
Chief Legal Officer and Corporate Secretary
Board of directors at ALUMIS.
Research analysts covering ALUMIS.
Recent press releases and 8-K filings for ALMS.
Alumis closes upsized public offering
ALMS
- Alumis Inc. announced the closing of its upsized underwritten public offering, which included the full exercise of the underwriters' option to purchase additional shares.
- The offering involved the sale of 20,297,500 shares of common stock at a price of $17.00 per share.
- This transaction generated approximately $345.1 million in gross proceeds for Alumis.
5 days ago
Alumis Inc. Announces Public Offering and Preliminary Cash Balance
ALMS
- Alumis Inc. entered into an underwriting agreement on January 7, 2026, for a public offering of 20,297,500 shares of its voting common stock, which includes 2,647,500 shares from a fully exercised option.
- The shares were offered at $17.00 per share, with the offering expected to close on January 9, 2026, generating approximately $345.1 million in gross proceeds for the company before deductions.
- As of December 31, 2025, the company reported preliminary unaudited cash, cash equivalents, and marketable securities of approximately $308.6 million.
6 days ago
Alumis Prices Upsized Public Offering of Common Stock
ALMS
- Alumis Inc. (Nasdaq: ALMS) announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock.
- The shares are priced at $17.00 per share, expected to generate approximately $300.0 million in gross proceeds for Alumis.
- All shares in the offering are being sold by Alumis.
- The offering is expected to close on January 9, 2026.
- Alumis has granted the underwriters a 30-day option to purchase up to an additional 2,647,500 shares of common stock.
7 days ago
Alumis Announces Proposed Public Offering of Common Stock
ALMS
- Alumis Inc. announced plans on January 6, 2026, to commence an underwritten public offering of $175.0 million of its common stock.
- The company expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares of its common stock.
- All shares in the proposed offering are being offered by Alumis.
- Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are acting as joint book-running managers for the offering.
Jan 6, 2026, 9:12 PM
Alumis Announces Positive Phase III Results for Envudeucitinib in Psoriasis
ALMS
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Alumis announced positive Phase III results for Envudeucitinib, its next-generation TYK2 inhibitor, in patients with moderate to severe plaque psoriasis, demonstrating highly statistically significant efficacy on primary and all secondary endpoints.
- Envudeucitinib achieved 74% PASI 75 and 59% sPGA 0/1 at week 16, and approximately 65% PASI 90 and over 40% PASI 100 at week 24, alongside a favorable safety profile.
- The company plans to file a New Drug Application (NDA) for Envudeucitinib in psoriasis in the second half of 2026.
- Alumis anticipates sharing top-line data from a potentially pivotal Phase IIb trial of Envudeucitinib in Systemic Lupus Erythematosus (SLE) in Q3 2026.
- The global psoriasis market is projected to reach $40 billion by 2030, with Envudeucitinib positioned to drive growth if approved.
Jan 6, 2026, 1:00 PM
Alumis Announces Positive Phase 3 Results for Nvudusitinib in Psoriasis
ALMS
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Alumis (ALMS) announced positive Phase 3 results for Nvudusitinib, its next-generation TYK2 inhibitor, in moderate to severe plaque psoriasis, demonstrating highly statistically significant efficacy on primary and all secondary endpoints and a favorable safety and tolerability profile.
- Nvudusitinib achieved 74% PASI 75 and 59% sPGA 0/1 at week 16, and approximately 65% PASI 90 and over 40% PASI 100 on average across both trials at week 24, with rapid onset of action.
- The company plans to file a New Drug Application (NDA) in the second half of 2026 for psoriasis and anticipates top-line data from a potentially pivotal Phase 2b trial in SLE in Q3 2026.
- The global psoriasis market is projected to reach $40 billion by 2030, with high-efficacy orals like Nvudusitinib expected to drive this growth.
Jan 6, 2026, 1:00 PM
Alumis Announces Positive Phase 3 Results for Envudeucitinib in Psoriasis
ALMS
New Projects/Investments
Product Launch
Guidance Update
- Alumis' Envudeucitinib (TYK2 inhibitor) ONWARD1 and ONWARD2 Phase 3 trials for plaque psoriasis successfully met all primary and secondary endpoints, demonstrating highly statistically significant efficacy and a favorable safety profile.
- Envudeucitinib achieved 74% PASI 75 and 59% sPGA 0/1 at Week 16, with skin clearance deepening to 65% PASI 90 and >40% PASI 100 by Week 24.
- The company plans to file a New Drug Application (NDA) for Envudeucitinib in psoriasis in the second half of 2026.
- Additionally, Phase 2b LUMUS SLE topline results for Envudeucitinib are anticipated in Q3 2026.
Jan 6, 2026, 1:00 PM
Alumis Announces Positive Phase 3 Results for Nvudusitinib in Psoriasis
ALMS
Product Launch
New Projects/Investments
- Alumis announced positive Phase 3 results for its next-generation TYK2 inhibitor, Nvudusitinib, in moderate to severe plaque psoriasis.
- The Onward Phase 3 trials met all primary and secondary endpoints with high statistical significance, demonstrating 74% PASI 75 and 59% sPGA 0/1 at week 16, and deepening to approximately 65% PASI 90 and over 40% PASI 100 by week 24 (averaged across studies).
- Nvudusitinib showed a favorable safety and tolerability profile, consistent with its Phase 2 program, with a very low single-digit discontinuation rate due to adverse events.
- The company plans to file a New Drug Application (NDA) for Nvudusitinib towards the end of 2026, pending data from the randomized withdrawal portion of the Phase 3 trial.
- Alumis expects top-line data from a Phase 2b trial of Nvudusitinib in SLE in Q3 2026 and plans to initiate a Phase 2 trial for its second candidate, A005, in MS in H1 2026.
Jan 6, 2026, 1:00 PM
Alumis announces positive Phase 3 results for envudeucitinib in plaque psoriasis
ALMS
Product Launch
New Projects/Investments
- Alumis Inc. announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials for envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis.
- Envudeucitinib met all primary and secondary endpoints with high statistical significance, with approximately 65% of patients achieving PASI 90 and more than 40% achieving PASI 100 at Week 24, on average across both trials.
- The drug demonstrated a favorable safety and tolerability profile consistent with its Phase 2 program.
- Alumis plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.
- Topline data from the LUMUS Phase 2b trial of envudeucitinib in systemic lupus erythematosus (SLE) are expected to be announced in the third quarter of 2026.
Jan 6, 2026, 12:12 PM
Alumis Reports Third Quarter 2025 Financial Results and Anticipates Key Clinical Data Readouts
ALMS
Earnings
Guidance Update
New Projects/Investments
- Alumis Inc. reported a net loss of $110.8 million and $2.1 million in collaboration revenue for the third quarter ended September 30, 2025.
- As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $377.7 million, which is projected to support operations into 2027.
- The company anticipates key clinical data readouts, including topline Phase 3 ONWARD data for envudeucitinib in moderate-to-severe plaque psoriasis early in Q1 2026, and topline Phase 2b LUMUS data in systemic lupus erythematosus in Q3 2026.
Nov 13, 2025, 9:17 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more